Screener / SEC EDGAR /CIK 0000313143 /10-K filed May 20, 2026, compared with May 21, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Haemonetics Corp HAE

Compare with peers Embed
The 10-K against last year's

116 changes: 28 added, 16 removed, 71 reworded, 1 quiet changes

10-K May 20, 2026 vs May 21, 2025

10-K 0000313143-26-000050 (May 20, 2026) vs 10-K 0000313143-25-000025 (May 21, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

107 paragraphs · 4 new · 38 reworded · 1 gone · 10-K May 20, 2026 against May 21, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 75 · 31% changed Every version of it
We market and sell our products in approximately 90 countries and have distributors in approximately 87 of these countries. This exposes us to currency fluctuation, geopolitical risk, economic volatility, anti-corruption laws, export and import restrictions, local regulatory authorities and the laws and medical practices in foreign jurisdictions. Recently, the U.S. legislation government implemented substantial changes to U.S. trade policies, including increased tariffs and executive orders aimed at boosting competitiveness changes to multilateral trade agreements. Additionally, the President of the United States has directed various federal agencies to further evaluate key aspects of U.S. businesses trade policy and there has been ongoing discussion and commentary regarding potential significant changes to U.S. trade policies, treaties and tariffs. Global trade policy continues to evolve and the ultimate impact of recent developments with respect to U.S. tariffs is unclear. There remains substantial uncertainty regarding the duration of existing and newly announced tariffs, potential changes or pauses to such tariffs, tariff levels, and whether further additional tariffs or other retaliatory actions may have unintended effects be imposed, modified, or suspended, and the impacts of such actions on our business. Tariffs and other measures directed at China, Mexico, Canada and other markets enacted by These developments, or the U.S., countervailing measures perception that may be enacted by various countries, as well as prolonged uncertainty regarding such measures as administrations change, any of them could occur, may have a material adverse effects effect on global economic conditions and the stability of global financial markets, and may significantly reduce global trade and, in particular, trade between the impacted nations and the U.S. These changes could prevent or make it difficult or more expensive for us to obtain the materials or components needed for new products. Tariff increases could negatively impact our costs and/or require us to increase our prices, which likely would decrease customer demand for our products. Retaliatory tariff and trade measures imposed by other countries could affect our ability to source, manufacture export products and distribute products, therefore adversely affect our sales. Any significant changes in current U.S. trade or receive payments, other policies that restrict imports or increase import tariffs could have a material adverse effect upon our results of operations. Further, in a timely and cost-effective manner, thereby adversely affecting our business. In addition to fluctuations in foreign exchange rates, discussed below, our business in markets outside the United States is subject to changing political, social and geopolitical conditions, such as tensions between China and Taiwan and the wars in Ukraine Ukraine, Iran and other parts of the Middle East, including any political instability resulting from war, terrorism, insurrections and civil unrest, and changing economic conditions in these markets, such as inflation, deflation, interest rate volatility and credit availability. Additionally, a number of factors, including U.S. relations with the governments of the foreign countries in which we operate, changes to international trade agreements and treaties, changes in tax laws and regulations, economic sanctions (including those imposed by the U.S. and other governments against Russia), export controls, restrictions on the ability to transfer capital across borders, tariffs and other increases in trade protectionism and barriers to market participation, or the weakening or loss of certain intellectual property protection rights in some countries, may affect our business, financial condition and results of operations. Many of these risks are rapidly evolving and subject to an accelerating pace of change. We are continuing to monitor the situation situations in Ukraine Ukraine, Iran and other parts of the Middle East and globally as well as to assess its potential impact on our business. Although our business in Russia accounted for only about less than 1% of fiscal 2025 2026 net revenues, a significant escalation or further expansion of the conflict’s current scope or related disruptions to the global markets could have a material adverse effect on our results of operations.
Paragraph 5 · 29% changed Every version of it
In fiscal 2025, 2026, our ten largest customers accounted for approximately 42% 44% of our net revenues. Although we did not have any customers that represented more than 10% of our consolidated revenues in fiscal 2025, a A material portion of sales in our Plasma segment come from (and we anticipate will continue to come from) a limited number of customers. As previously disclosed, In fiscal 2026, one Plasma customer accounted for approximately 13% of our largest Plasma customers, CSL, informed us in April 2021 of its intent not to renew its supply agreement for the use of PCS2® plasma collection system devices and the purchase of disposable plasmapheresis kits in the U.S. following the expiration of the then current term of its contract, which was subsequently extended on a non-exclusive basis through December 2025. total net revenues. Any non-renewal, termination, material reduction in purchasing or material reduction in per unit pricing by any of our largest customers for any reason, including material decreases in demand for plasma or development of alternative processes, could have a material adverse effect on our business, financial condition or results or operations.
Paragraph 16 · 20% changed Every version of it
We increasingly rely on information technology systems, including cloud-based computing, to process, transmit and store electronic information for our day-to-day operations and for our customers, including sensitive personal information and proprietary or confidential information. Additionally, certain of our products collect data regarding patients and donors and connect to our systems for maintenance and other purposes or are actively managed by Haemonetics on behalf of specific customers. Similar to other large multi-national companies, the size and complexity of our information technology systems makes them vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy, or other significant disruption. We outsource certain elements of our information technology systems to third parties that, as a result of this outsourcing, could have access to certain confidential information and whose systems may also be vulnerable to these types of attacks or disruptions. While we conduct security risk assessments prior to engaging third-party suppliers and other vendors and business partners to validate that they maintain appropriate safeguards to protect our and their information systems in connection with the services they provide, it is possible that they suffer a cyber-attack that impacts us, our suppliers or our customers. Security threats, including cyber and other attacks are becoming increasingly sophisticated, frequent, and adaptive and, like other large multi-national companies, we have experienced cyber incidents in the past and may experience them in the future. Accordingly, our information systems require an ongoing commitment of significant resources to maintain, protect and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards, the increasing need to protect patient and customer information and changing customer patterns. This includes opportunities as well as risks associated with the integration of AI into our or our suppliers’ or customers’ operations. While AI presents significant opportunities for innovation and efficiency, it could also introduce new risks in managing information systems and in the cybersecurity threat landscape. Based on the information available as of the date of this Annual Report on Form 10-K, we are not aware of any risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operation or financial condition. While we have invested and continue to invest in the protection of personal information and proprietary or confidential information, there can be no assurance that our efforts will prevent cyber-attacks, intrusions, breakdowns or other incidents or ensure compliance with all applicable securities and privacy laws, regulations, standard regulations and standards. In addition, third parties may attempt to hack into our products to obtain data relating to patients with our products or our proprietary information. Emerging technologies such as generative AI may be used by malicious actors to create more targeted phishing narratives or otherwise strengthen social engineering capabilities, which may increase our threat landscape. Any failure by us or third parties we work with to maintain or protect our respective information technology systems and data integrity, including from cyber-attacks, intrusions or other breaches, could result in the unauthorized access to patient data and personally identifiable information, theft of intellectual property or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Any of these events, in turn, may cause us to lose existing customers, have difficulty preventing, detecting and controlling fraud, have disputes with customers, physicians and other healthcare professionals, be subject to legal claims and liability, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur expenses or lose revenues as a result of a data privacy breach or theft of intellectual property, or suffer other adverse consequences, any of which could have a material adverse effect on our business, financial condition or results of operations.
Paragraph 54 · 15% changed Every version of it
We are subject to income taxes, non-income based taxes and tax audits in the U.S. and various foreign jurisdictions. Tax authorities may disagree with certain positions we have taken and assess additional taxes. We regularly assess the likely outcomes of these audits in order to determine the appropriateness of our tax provision and have established contingency reserves for material, known tax exposures. However, the calculation of such tax exposures involves the application of complex tax laws and regulations in many jurisdictions, as well as interpretations as to the legality under various rules in certain jurisdictions. Therefore, there can be no assurance that we will accurately predict the outcomes of these disputes or other tax audits or that issues raised by tax authorities will be resolved at a financial cost that does not exceed our related reserves and the actual outcomes of these disputes and other tax audits could have a material impact on our results of operations or financial condition.
Paragraph 59 · 13% changed Every version of it
In April 2024, the Company entered into a second amended and restated credit agreement with certain lenders to refinance the existing senior unsecured term loan and senior unsecured revolving credit facility and extend their maturity date through April 2029. The second amended and restated credit agreement provides for a $250.0 million senior unsecured term loan and a $750.0 million senior unsecured revolving credit facility, or together, the 2024 Revised Credit Facilities. In May 2024, the Company issued $700.0 million aggregate principal amount of indebtedness under the Company’s convertible notes due 2029, or 2029 Notes, (“2029 Notes”), and used $230.0 million of the proceeds to repay the entirety of the previously outstanding balance under the Company’s senior unsecured revolving credit facility and $185.5 million of the proceeds to repurchase $200.0 million in aggregate principal amount of the Company’s convertible senior notes due 2026 (“2026 Notes”). In March 2026, or 2026 Notes. The the Company repaid the remaining $300.0 million balance of the 2026 Notes at maturity, funded by cash on hand and 2029 Notes are referred below collectively as $300.0 million of borrowings under the Notes. Company’s revolving credit facility. As of March 29, 2025, 28, 2026, the Company had $250.0 $239.1 million of debt outstanding under the senior unsecured term loan, $300.0 million aggregate principal amount of indebtedness under the 2026 Notes, and $700.0 million aggregate principal amount of indebtedness under the 2029 Notes. Notes, and $300.0 million outstanding under the revolving credit facility.
Paragraph 49 · 12% changed Every version of it
Under the FDA’s medical device reporting regulations, medical device manufacturers are required to report to the FDA information of which they become aware that a device has or may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or one of our similar devices were to recur. In addition, drug manufacturers are required to report adverse drug experiences associated with the use of a drug and submit field alert reports for instances of contamination, change or deterioration of the distributed product or failure to meet specifications. Similar reporting requirements exist in some of the other jurisdictions in which we operate. Failure to report these events to the FDA or other applicable regulatory authorities within the required timeframes, or at all, could lead to enforcement actions, fines and criminal sanctions against us.
Paragraph 71 · 12% changed Every version of it
Certain provisions in the 2029 Notes and the Indentures could make a third party attempt to acquire us more difficult or expensive. For example, if a takeover constitutes a fundamental change, then noteholders will have the right to require us to repurchase their 2029 Notes for cash. In addition, if a takeover constitutes a make-whole fundamental change, then we may be required to temporarily increase the conversion rate. In either case, and in other cases, our obligations under the 2029 Notes and the Indentures could increase the cost of acquiring us or otherwise discourage a third party from acquiring us or removing incumbent management, including in a transaction that noteholders or holders of our common stock may view as favorable.
Paragraph 38 · 11% changed Every version of it
The manufacture, distribution and marketing of our products are subject to extensive regulation by the FDA and other state and non-U.S. regulatory bodies. Our operations are also subject to review and monitoring by the FDA and other regulatory authorities. Government regulation of medical devices is meant to assure their safety and effectiveness, and includes regulation of, among other things, the product’s development, testing, premarket clearance, de novo classification or approval, manufacture, marketing, labeling, post-market surveillance, reporting, and imports and exports. Before a new medical device, or a new use of an existing product product, can be marketed in the United States, it must first receive either premarket clearance under Section 510(k) of the U.S. Federal Food, Drug, and Cosmetic Act, or FDCA, a grant of a request for de novo classification or a Premarket Approval, premarket approval, or PMA, from the FDA, unless an exemption applies. Similarly, before For example, in 2025 Vivasure submitted a new drug can be marketed in PMA application to the U.S., it must first receive approval of a new drug application or abbreviated new drug application FDA for the PerQseal Elite arterial closure system that is currently under the FDCA. FDA review. The process of obtaining regulatory authorization to market a medical device or a drug can be costly and time-consuming, and we may not be able to obtain these authorizations on a timely basis, if at all.

MD&A

115 paragraphs · 24 new · 67 reworded · 15 gone · 10-K May 20, 2026 against May 21, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 7 · 48% changed
In February 2025, the Company entered into an ASR accordance with Goldman Sachs & Co. to our previously announced three-year share repurchase $150.0 million of the Company’s common stock and received an additional delivery of 2.0 million shares of the Company’s common stock based on a closing market price on the New York Stock Exchange on February 7, 2025 of $59.34, which represented 80% of the total contract. The ASR was completed in April 2025, subsequent to the end of program, During the fourth quarter of fiscal 2025, and 0.4 2026, we repurchased $25.0 million additional of our common stock pursuant to a previously executed Rule 10b5-1 trading plan. The total number of shares were delivered repurchased pursuant to the Rule 10b5-1 trading plan was 360,457 at an average price per share upon settlement. final settlement of $69.36. Additionally, in March 2026, we completed a $75.0 million repurchase of our common stock pursuant to an ASR entered into with Goldman Sachs in February 2026. The total number of shares repurchased under the ASR was 1,218,798 at an average price per share upon final settlement of $61.54. As of March 29, 2025, we have fully funded 28, 2026, the $300.0 million Share Repurchase Authorization. total remaining authorization for repurchases of our common stock under the share repurchase program was $325.0 million.
Paragraph 71 · 47% changed
Net cash provided by operating activities was $181.7 increased $111.5 million during fiscal 2025, relatively flat 2026 as compared with fiscal 2024. Operating cash 2025. Cash flows from operating activities for fiscal year 2025 benefited from higher 2026 included net income, lower accounts receivable income of $97.3 million, adjusted for non-cash depreciation and decreased accrued performance-based compensation, as compared to the fiscal 2024 period, amortization of $111.7 million, share-based compensation expense of $33.8 million and impairment charges of $86.5 million, partially offset by cash outflows for working capital of $23.7 million driven by digital transformation costs. Cash flows from operating activities for fiscal 2025 included net income of $167.7 million, adjusted for non-cash items including items, primarily depreciation and amortization of $115.6 million and share-based compensation of $29.6 million; partially offset by cash outflows for non-cash adjustments related to a $23.0 million gain on the remeasurement of contingent consideration consideration, a $15.7 million gain on the sale of property, plant and gains equipment, a $12.6 million gain on the repurchase of convertible senior notes notes, and sales cash outflows for working capital of property, plant and equipment. $102.0 million driven by increased outflows for inventory.
Paragraph 67 · 46% changed
In February April 2025, our Board approved a new three-year share repurchase program authorizing the Company repurchase of up to $500 million of our common stock, based on market conditions, through April 2028. In September 2025, we completed a $75.0 million repurchase of our common stock pursuant to an ASR entered into an ASR with Goldman Sachs & Co. to repurchase $150.0 million Citibank N.A. in August 2025. The total number of the Company’s common stock and received an additional delivery of 2.0 million shares of the Company’s common stock based on a closing market price on the New York Stock Exchange on February 7, 2025 of $59.34, which represented 80% of the total contract. The repurchased under this ASR was completed in April 2025, subsequent to the end 1,430,579 for an average price per share upon final settlement of $52.43. During the fourth quarter of fiscal 2025, and 0.4 2026, we repurchased $25.0 million additional of our common stock pursuant to a previously executed Rule 10b5-1 trading plan. The total number of shares were delivered repurchased pursuant to the Rule 10b5-1 trading plan was 360,457 at an average price per share upon settlement. final settlement of $69.36. Additionally, in March 2026 we completed a $75.0 million repurchase of our common stock pursuant to an ASR entered into with Goldman Sachs in February 2026. The total number of shares repurchased under this ASR was 1,218,798 for an average price per share upon final settlement of $61.54. As of March 29, 2025, we have fully funded 28, 2026, the $300.0 million Share Repurchase Authorization. total remaining authorization for repurchases of our common stock under the share repurchase program was $325.0 million.
Paragraph 52 · 44% changed
We recognized impairment of intangible assets of $2.4 $86.5 million and $10.4 $2.4 million during fiscal 2025 2026 and fiscal 2024, 2025, respectively. Impairment of intangible assets in fiscal 2026 related to the Attune Medical asset group and the intellectual property associated with the HAS viscoelastic diagnostic devices, related assays and disposables. Impairment of intangible assets in fiscal 2025 related to internally developed software assets. Impairment of intangible assets in fiscal 2024 related For further discussion, refer to Note 10, Goodwill & Intangible Assets within the enicor GmbH acquisition completed in fiscal 2021 within our Hospital business unit. accompanying consolidated financial statements for further information.
Paragraph 76 · 43% changed
Payments Due by Period (In thousands) Total Less than 1 year 1-3 years 3-5 years More than 5 years Convertible senior notes $ 1,000,000 $ 300,000 $ — $ 700,000 $ — Contingent consideration 2,278 44 2,234 — — Debt 246,120 6,349 17,307 222,010 454 Interest payments(1) 54,137 14,218 27,201 12,718 — Operating leases 71,536 10,835 20,869 15,056 24,776 Purchase commitments(2) 287,923 287,923 — — — Expected retirement plan benefit payments 19,906 1,553 3,149 4,030 11,174 Total contractual obligations $ 1,681,900 $ 620,922 $ 70,760 $ 953,814 $ 36,404 (1) Interest payments reflect the contractual interest payments on outstanding debt related to the term loan under our 2024 Revised Credit Facilities and exclude the impact of interest rate swap agreements. Interest payments are projected using interest rates in effect as of March 29, 2025. Certain of these projected interest payments may differ in the future based on changes in market interest rates. (2) Includes amounts we are committed to spend on purchase orders entered in the normal course of business for which includes capital equipment as well as and commitments with contractors for the manufacture of certain disposable products and equipment. The majority of our operating expense spending does not require any advance commitment.
Paragraph 102 · 43% changed
We review also evaluate long-lived intangible assets subject to amortization for intangible impairment at least annually or more frequently if certain conditions arise quarterly to determine if any adverse conditions exist that would indicate that the carrying value of an asset or asset group may not be recoverable, or that a change in the remaining useful life is required. Conditions indicating that an intangible impairment exists include but are not limited to a change in the competitive landscape, internal decisions to pursue new or different technology strategies, a loss of a significant customer or a significant change in the marketplace including prices paid for our products or the size of the market for our products. Recoverability is assessed by comparing the carrying value of the asset group to the undiscounted cash flows expected to result from its use and eventual disposition. If the carrying value exceeds those undiscounted cash flows, an intangible impairment loss is measured as the excess of carrying value over fair value.
Paragraph 49 · 42% changed
Research Selling, general and development administrative expenses increased 15.2% 1.3% on an as reported basis and increased 0.2% without the effect of foreign exchange during fiscal 2025 2026 as compared with fiscal 2024. Without the effects of foreign exchange, research and development expenses increased 15.6% during fiscal 2025. The increase in fiscal 2025 2026 was primarily due to increased headcount as a result costs associated with the acquisition of recent acquisitions. Vivasure, impacts from tariffs and higher performance-based compensation costs.
Paragraph 75 · 41% changed
Payments Due by Period (In thousands) Total Less than 1 year 1-3 years 3-5 years More than 5 years Convertible senior notes $ 1,000,000 $ 300,000 $ — $ 700,000 $ — Contingent consideration 2,278 44 2,234 — — Debt 246,120 6,349 17,307 222,010 454 Interest payments(1) 54,137 14,218 27,201 12,718 — Operating leases 71,536 10,835 20,869 15,056 24,776 Purchase commitments(2) 287,923 287,923 — — — Expected retirement plan benefit payments 19,906 1,553 3,149 4,030 11,174 Total contractual obligations $ 1,681,900 $ 620,922 $ 70,760 $ 953,814 $ 36,404 (1) Interest payments reflect the contractual interest payments on outstanding debt related to the term loan under our 2024 Revised Credit Facilities and exclude the impact of interest rate swap agreements. Interest payments are projected using interest rates in effect as of March 29, 2025. 28, 2026. Certain of these projected interest payments may differ in the future based on changes in market interest rates. (2) Includes amounts we are committed to spend on purchase orders entered in the normal course of business for capital equipment as well as commitments with contractors for the manufacture of certain disposable products and equipment. The majority of our operating expense spending does not require any advance commitment.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors377 words changed in this paragraph; it is 58% similar to last year's version.
We market and sell our products in approximately 90 countries and have distributors in approximately 87 of these countries. This exposes us to currency fluctuation, geopolitical risk, economic volatility, anti-corruption laws, export and import restrictions, local regulatory authorities and the laws and medical practices in foreign jurisdictions. Recently, the U.S. legislation government implemented substantial changes to U.S. trade policies, including increased tariffs and executive orders aimed at boosting competitiveness changes to multilateral trade agreements. Additionally, the President of the United States has directed various federal agencies to further evaluate key aspects of U.S. businesses trade policy and there has been ongoing discussion and commentary regarding potential significant changes to U.S. trade policies, treaties and tariffs. Global trade policy continues to evolve and the ultimate impact of recent developments with respect to U.S. tariffs is unclear. There remains substantial uncertainty regarding the duration of existing and newly announced tariffs, potential changes or pauses to such tariffs, tariff levels, and whether further additional tariffs or other retaliatory actions may have unintended effects be imposed, modified, or suspended, and the impacts of such actions on our business. Tariffs and other measures directed at China, Mexico, Canada and other markets enacted by These developments, or the U.S., countervailing measures perception that may be enacted by various countries, as well as prolonged uncertainty regarding such measures as administrations change, any of them could occur, may have a material adverse effects effect on global economic conditions and the stability of global financial markets, and may significantly reduce global trade and, in particular, trade between the impacted nations and the U.S. These changes could prevent or make it difficult or more expensive for us to obtain the materials or components needed for new products. Tariff increases could negatively impact our costs and/or require us to increase our prices, which likely would decrease customer demand for our products. Retaliatory tariff and trade measures imposed by other countries could affect our ability to source, manufacture export products and distribute products, therefore adversely affect our sales. Any significant changes in current U.S. trade or receive payments, other policies that restrict imports or increase import tariffs could have a material adverse effect upon our results of operations. Further, in a timely and cost-effective manner, thereby adversely affecting our business. In addition to fluctuations in foreign exchange rates, discussed below, our business in markets outside the United States is subject to changing political, social and geopolitical conditions, such as tensions between China and Taiwan and the wars in Ukraine Ukraine, Iran and other parts of the Middle East, including any political instability resulting from war, terrorism, insurrections and civil unrest, and changing economic conditions in these markets, such as inflation, deflation, interest rate volatility and credit availability. Additionally, a number of factors, including U.S. relations with the governments of the foreign countries in which we operate, changes to international trade agreements and treaties, changes in tax laws and regulations, economic sanctions (including those imposed by the U.S. and other governments against Russia), export controls, restrictions on the ability to transfer capital across borders, tariffs and other increases in trade protectionism and barriers to market participation, or the weakening or loss of certain intellectual property protection rights in some countries, may affect our business, financial condition and results of operations. Many of these risks are rapidly evolving and subject to an accelerating pace of change. We are continuing to monitor the situation situations in Ukraine Ukraine, Iran and other parts of the Middle East and globally as well as to assess its potential impact on our business. Although our business in Russia accounted for only about less than 1% of fiscal 2025 2026 net revenues, a significant escalation or further expansion of the conflict’s current scope or related disruptions to the global markets could have a material adverse effect on our results of operations.

Source: Item 1A, 10-K 0000313143-26-000050 vs Item 1A, 10-K 0000313143-25-000025

Legal Proceedings169 words changed in this paragraph; it is 43% similar to last year's version.
During the first quarter of fiscal 2026, the Company filed a complaint against Terumo BCT in U.S. District Court for the District of Colorado. Colorado (1:25-cv-01409). The complaint alleges that Terumo BCT infringes the Company’s intellectual property rights with respect to its donor-centric blood plasma collection patents, as embodied in our the Company’s NexSys PCS® with YES® technology and NexSys PCS with Persona® technology. While we will incur costs On June 26, 2025, Terumo filed a motion to dismiss. On July 17, 2025 and August 12, 2025, the Company filed amended complaints adding recently issued patents. On September 2, 2025, Terumo filed a partial motion to dismiss with prejudice claiming that the Company’s asserted patents were invalid under 35 U.S.C. section 101. Terumo has also filed inter partes and post-grant review petitions with the U.S. Patent and Trademark Office (PTO) seeking to invalidate the asserted patents. In October 2025, Terumo filed a motion to stay the district court proceedings pending resolution of the PTO petitions. The Company filed responses opposing Terumo’s motions in November 2025. Two of the course nine PTO petitions have been instituted for further review, and seven of pursuing this claim, and the outcome of litigation is inherently uncertain, we believe this is a necessary and appropriate action to safeguard our innovations, protect our intellectual property, and further PTO petitions were denied by the growth and development of our business. PTO.

Source: Item 3, via Note 15 – COMMITMENTS AND CONTINGENCIES, 10-K 0000313143-26-000050 vs Item 3, via Note 15 – COMMITMENTS AND CONTINGENCIES, 10-K 0000313143-25-000025

MD&A163 words changed in this paragraph; it is 33% similar to last year's version.
Net cash used in financing activities decreased $287.3 million during fiscal 2026 as compared to net cash provided by financing activities was $108.8 million during fiscal 2025, an increase 2025. Cash flows used in financing activities for fiscal 2026 included cash outflows for the repayment of $70.7 million as compared with the 2026 Notes of $300.0 million, share repurchases of $175.0 million, repayments of term loan borrowings of $6.3 million, and employee equity award settlements of $5.0 million, partially offset by proceeds from the revolving credit facility of $300.0 million. Cash flows provided by financing activities for fiscal 2024, primarily due 2025 included cash inflows relating to proceeds from the issuance of the 2029 Notes, Notes of $700.0 million and proceeds from term loan borrowings of $250.0 million, partially offset by cash outflows for the repurchase of a portion of the 2026 Notes, proceeds on the revolving credit facility in the previous year, Notes of $185.5 million, capped call transactions, share repurchases, purchases of $88.2 million, term loan redemptions of $262.5 million, shares repurchases of $225.0 million, payments on the revolving credit facility in the current year and of $50.0 million, debt issuance costs. costs of $23.1 million and employee equity award settlements of $10.2 million.

Source: Item 7, 10-K 0000313143-26-000050 vs Item 7, 10-K 0000313143-25-000025

Accounting Policies137 words changed in this paragraph; it is 45% similar to last year's version.
During In fiscal 2026 the fourth quarters of Company elected to perform the annual goodwill impairment test using qualitative assessments for three reporting units and a quantitative assessment for one reporting unit for its annual goodwill impairment test. In fiscal 2025 and 2023, 2025, the Company elected to perform quantitative assessments for its annual goodwill impairment test, whereas in test. In fiscal 2024, the Company performed a qualitative assessment. In fiscal 2025, 2024 2026, 2025 and 2023, 2024, the results of the annual goodwill impairment test performed indicated that the estimated fair value of all of its reporting units exceeded their respective carrying values and there were no reporting units at risk of impairment as values, however, in fiscal 2026 the fair value of the annual test dates. Interventional Technologies reporting unit, which is within the Hospital reportable segment, was $867.8 million, which only exceeded its carrying value of $821.6 million by 6%. The fair value of the Interventional Technologies reporting unit was primarily determined using a discounted cash flow approach utilizing a discount rate of 10.5%, which reflects a market-participant weighted average cost of capital based on the risk profile, size, and capital structure of the reporting unit.

Source: Item 8, Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0000313143-26-000050 vs Item 8, Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0000313143-25-000025

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of HAE's Risk Factors and MD&A, 10-K May 20, 2026 against 10-K May 21, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
We are in the process of implementing a new global enterprise resource planning system. This system will replace many of our existing operating and financial systems. The implementation is a major undertaking, both financially and from a management and personnel perspective. Any material disruptions, delays or deficiencies in the design and implementation of our new enterprise resource planning system could adversely affect our ability to process orders, ship products, provide services and customer support, send invoices and track payments, fulfill contractual obligations or otherwise operate our business.
Read it in 10-K May 20, 2026 at sec.gov
AddedRisk Factors
Additionally, FDA and foreign regulations and guidance are often revised or reinterpreted by the FDA and foreign counterparts in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance, approval, or certification to manufacture, market or distribute our products. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to obtaining clearance, approval, or certification; changes to manufacturing methods; recall, replacement or discontinuance of our products; or additional record keeping. For example, on February 2, 2026, the FDA’s final rule implementing the QMSR became effective. The QMSR, which replaced the FDA’s former Quality System Regulation, sets forth the FDA’s cGMP requirements for medical devices, and among other things, incorporates by reference certain elements of the quality management system requirements of ISO 13485:2016. Although the FDA has stated that the standards contained in ISO 13485:216 are substantially similar to those set forth in the QSR, and although we have obtained ISO 13485:2016 certification for our quality management system, the FDA has indicated that ISO:13485 certification alone will not ensure compliance under the QMSR, nor will ISO certification exempt manufacturers from FDA inspection. The QMSR also includes certain compliance obligations, such as those relating to unique device identification, product traceability, and maintenance of complaint and service records, which align more closely with FDA’s existing medical device requirements than with ISO standards. Accordingly, it remains unclear the extent to which the QMSR may impose additional or different regulatory requirements on us that could increase the costs of compliance or otherwise negatively affect our business. If we are unable to comply with QMSR or with any other changes in the laws or regulations enforced by FDA or comparable regulatory authorities, we may be subject to enforcement action, which could have an adverse effect on our business, financial condition and results of operations.
Read it in 10-K May 20, 2026 at sec.gov
AddedRisk Factors
The One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. on July 4, 2025. The OBBBA legislation provides for the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act of 2017, revisions to the international tax framework and the reinstatement of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented in future periods. The Company has accounted for the impact of the OBBBA on the Company’s consolidated financial statements and has determined that it has no material impact on the reported tax rate in the current year.
Read it in 10-K May 20, 2026 at sec.gov
RemovedRisk Factors
The influence of integrated delivery networks, group purchasing organizations and large single accounts has the potential to put price pressure on our Hospital business. It also puts price pressure on our U.S. Blood Center customers who are also facing reduced demand for red cells. Our Blood Center customers have responded to this pressure by creating their own group purchasing organizations and resorting to single source tenders to create incentives for suppliers, including us, to significantly reduce prices.
Read it in 10-K May 21, 2025 at sec.gov
RewordedRisk Factors
Similarly, the separation of states from participation in the EU, such as through the cessation of the United Kingdom’s membership in the EU (commonly known as “Brexit”) Brexit and the separation of the Swiss and EU medical product markets with the adoption of the EU MDR (commonly referred to as “Swexit”), Swexit, may result in further regulatory risk and complexity as the former EU member or participant state establishes separate laws and regulations governing medical products.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
As of March 29, 2025, 28, 2026, the Company had $250.0 $239.1 million of debt outstanding under the senior unsecured term loan, $300.0 million aggregate principal amount of indebtedness under the 2026 Notes, and $700.0 million aggregate principal amount of indebtedness under the 2029 Notes. Notes, and $300.0 million outstanding under the revolving credit facility.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
Although our share repurchase program is intended to enhance long-term shareholder value, short-term stock price fluctuations could reduce the program’s effectiveness Refer to Note 7, Earnings per Share, to within the Consolidated Financial Statements consolidated financial statements in Item 8 of this Annual Report on Form 10-K for additional information.
Read it in 10-K May 20, 2026 at sec.gov
Show the other 46
RewordedRisk Factors
Although our share repurchase program is intended to enhance long-term shareholder value, short-term stock price fluctuations could reduce the program’s effectiveness Refer to Note 7, Earnings per Share, to the Consolidated Financial Statements in Item 8 of this Annual Report on Form 10-K for additional information. effectiveness.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
Before a new medical device, or a new use of an existing product product, can be marketed in the United States, it must first receive either premarket clearance under Section 510(k) of the U.S. FDCA, a grant of a request for de novo classification or a premarket approval, or PMA, from the FDA, unless an exemption applies.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
Although we did not have any customers that represented more than 10% of our consolidated revenues in fiscal 2025, a A material portion of sales in our Plasma segment come from (and we anticipate will continue to come from) a limited number of customers.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
We are continuing to monitor the situation situations in Ukraine Ukraine, Iran and other parts of the Middle East and globally as well as to assess its potential impact on our business.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
We are required to comply with increasingly complex and changing legal and regulatory requirements that govern the collection, use, storage, security, transfer, disclosure and other processing of personal data in the United States and in other countries, including, but not limited to, HIPAA, HITECH, the California Consumer Privacy Act, or CCPA, Act (“CCPA), the California Privacy Rights Act, and the EU’s General Data Protection Regulation, or GDPR. Regulation (“GDPR”).
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
In May 2024, the Company issued $700.0 million aggregate principal amount of indebtedness under the Company’s convertible notes due 2029, or 2029 Notes, (“2029 Notes”), and used $230.0 million of the proceeds to repay the entirety of the previously outstanding balance under the Company’s senior unsecured revolving credit facility and $185.5 million of the proceeds to repurchase $200.0 million in aggregate principal amount of the Company’s convertible senior notes due 2026, or 2026 Notes. (“2026 Notes”).
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
In Further, in addition to fluctuations in foreign exchange rates, discussed below, our business in markets outside the United States is subject to changing political, social and geopolitical conditions, such as tensions between China and Taiwan and the wars in Ukraine Ukraine, Iran and other parts of the Middle East, including any political instability resulting from war, terrorism, insurrections and civil unrest, and changing economic conditions in these markets, such as inflation, deflation, interest rate volatility and credit availability.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
A default under an the Indenture or the fundamental change itself could also lead to a default under agreements governing our other indebtedness, including our 2024 Revised Credit Facilities and the other Notes, Facilities, which may result in that other indebtedness becoming immediately payable in full.
Read it in 10-K May 20, 2026 at sec.gov
AddedMD&A
On January 9, 2026, we acquired all of the outstanding equity interests of Vivasure for a net purchase price of $164.4 million. The net purchase price included $60.2 million paid in cash at closing, net of $0.4 million cash acquired and after giving effect to the value of certain prior investments and loans we made to Vivasure, as well as other customary closing adjustments, and the fair value of contingent consideration of $20.7 million. The contingent consideration is based on sales growth over the three years following the completion of the acquisition and the achievement of certain other milestones, and is also subject to adjustments based on the value of certain prior investments and loans. The Company financed this transaction through available cash on hand.
Read it in 10-K May 20, 2026 at sec.gov
AddedMD&A
Vivasure is a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure. Vivasure’s PerQseal Elite system uses a proprietary bioabsorbable patch to seal large-bore (up to 26 F) arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures. In 2025, Vivasure submitted a premarket approval, or PMA, application to the FDA for the PerQseal Elite arterial closure system and received CE Mark in Europe for both arterial and venous indications. The addition of Vivasure expands our Hospital business unit portfolio in the interventional cardiology market and will be included in the Hospital reportable segment.
Read it in 10-K May 20, 2026 at sec.gov
AddedMD&A
On March 2, 2026, we repaid in full at maturity our outstanding 2026 Notes for an aggregate amount of $300.0 million in cash, representing the outstanding principal amount of the 2026 Notes. The repayment was funded with cash on hand and borrowings under the Company’s revolving credit facility. No holders exercised conversion rights with respect to the 2026 Notes prior to the close of business on the second scheduled trading day immediately preceding the maturity date. The capped call transactions entered into in connection with the issuance of the 2026 Notes expired in accordance with their terms upon the maturity of the 2026 Notes.
Read it in 10-K May 20, 2026 at sec.gov
AddedMD&A
Net revenues decreased 2.0% during fiscal 2026 as compared with fiscal 2025. The decrease was driven by prior year portfolio transitions in Plasma and Blood Center—including the previously announced customer transition of CSL Plasma and the divestiture of the Whole Blood product line—that together represented approximately $153 million of nonrecurring fiscal 2025 revenue, partially offset by an increase in Hospital, primarily attributable to the Hemostasis Management and Transfusion Management product lines within the Blood Management Technologies franchise.
Read it in 10-K May 20, 2026 at sec.gov
AddedMD&A
Interest and other expenses, net increased 194.5% during fiscal 2026 as compared with fiscal 2025. The increase was primarily driven by gains recognized in the first quarter of fiscal 2025 on the repurchase of $200.0 million of aggregate principal of our 2026 Notes. For further discussion on the 2026 Notes, refer to Note 12, Notes Payable and Long-Term Debt within the accompanying consolidated financial statements for further information.
Read it in 10-K May 20, 2026 at sec.gov
AddedMD&A
(1) Availability under our revolving credit facilities is reduced by eligible outstanding letters of credit allowable of $1.3 million as of March 28, 2026 and March 29, 2025, respectively.
Read it in 10-K May 20, 2026 at sec.gov
AddedMD&A
On March 2, 2026, we repaid in full at maturity our 2026 Notes for an aggregate amount of $300.0 million in cash, representing the outstanding principal amount of the 2026 Notes. The repayment was funded with cash on hand and borrowings under the Company’s revolving credit facility. No holders exercised conversion rights with respect to the 2026 Notes prior to maturity. The capped call transactions entered into in connection with the issuance of the 2026 Notes expired in accordance with their terms upon the maturity of the 2026 Notes.
Read it in 10-K May 20, 2026 at sec.gov
AddedMD&A
Goodwill is tested for impairment at least annually as of the first day of the fourth quarter in fiscal 2026, or more frequently if events or changes in circumstances indicate potential goodwill impairment. The test is performed at the reporting unit level by comparing the estimated fair value of each reporting unit to its carrying value, including goodwill.
Read it in 10-K May 20, 2026 at sec.gov
RemovedMD&A
On December 3, 2024, we announced that we entered into a definitive agreement to sell our Whole Blood product line and related assets within our Blood Center business unit to GVS, S.p.A (“GVS”), a manufacturer of filter solutions for applications in the healthcare and life sciences sectors. The divested assets include our complete portfolio of proprietary whole blood collection, processing and filtration solutions, along with our manufacturing facility in Covina, California where certain of these products are produced, and related equipment and assets located at our manufacturing facility in Tijuana, Mexico. On January 13, 2025, we completed the transaction with GVS for total cash consideration of up to $65.8 million, which includes $43.3 million upfront and up to $22.5 million in contingent consideration, based on sales growth over the next three years and the achievement of certain other milestones. As part of the transaction, we divested $26.4 million of inventory, $7.8 million of property, plant and equipment and $6.4 million of goodwill allocated based on fair value previously recorded in the Blood Center reportable segment in the Consolidated Balance Sheets. We recognized a gain on sale related to the divestiture which was not material.
Read it in 10-K May 21, 2025 at sec.gov
RemovedMD&A
In April 2025, our Board of Directors approved a new share repurchase authorization of up to $500.0 million of Haemonetics common stock over the next three years. This new share repurchase program will help to offset the dilutive impact of recent and future employee equity grants. The timing and amounts of activity under the repurchase program will be at management’s discretion. In addition to this share repurchase activity, our capital allocation strategy continues to prioritize funding of planned internal investments to support the business as well as inorganic opportunities to accelerate our long-term growth plans.
Read it in 10-K May 21, 2025 at sec.gov
RemovedMD&A
On May 28, 2024, we issued $700.0 million aggregate principal amount of 2.5% convertible senior notes due 2029 (the “2029 Notes”). The 2029 Notes are governed by the terms of the Indenture between us and U.S. Bank Trust Company, National
Read it in 10-K May 21, 2025 at sec.gov
RemovedMD&A
Association, as trustee. The total net proceeds from the sale of the 2029 Notes, after deducting the initial purchasers’ discounts and debt issuance costs, were $682.8 million, of which $230.0 million was used to repay the entirety of the previously outstanding balance on the Company’s senior unsecured revolving credit facility, $185.5 million was used to repurchase $200.0 million in aggregate principal amount of the Company’s 0% convertible senior notes due 2026 and $88.2 million was used to complete capped call transactions, with the remaining proceeds available for other working capital requirements. The 2029 Notes will mature on June 1, 2029, unless earlier converted, redeemed or repurchased.
Read it in 10-K May 21, 2025 at sec.gov
RemovedMD&A
On April 1, 2024, we completed our acquisition of Attune Medica for total consideration of $187.7 million, which included an upfront cash payment of $162.0 million, or $150.5 million net of cash acquired, the fair value of contingent consideration of $25.3 million, and $0.4 million of working capital adjustments. The contingent consideration is based on sales growth over the next three years, which is uncapped, and the achievement of certain other milestones. We financed the acquisition through a combination of cash on hand and borrowings under our senior unsecured revolving credit facility.
Read it in 10-K May 21, 2025 at sec.gov
RemovedMD&A
Attune Medical's ensoETM technology is designed for use across a range of medical conditions involving patient cooling or warming, including treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery, among others. The addition of our Esophageal Protection product line through this acquisition expands our Hospital business unit’s presence in electrophysiology and complements our Vascular Closure product line within Interventional Technologies, which is included in the Hospital reportable segment.
Read it in 10-K May 21, 2025 at sec.gov
RemovedMD&A
On October 10, 2023, we entered into an Arrangement Agreement with OpSens Inc. (“OpSens”), a medical device cardiology-focused company delivering solutions based on its proprietary optical technology, pursuant to which, among other things, we agreed to acquire all of the issued and outstanding common shares of OpSens. On December 12, 2023, we completed our acquisition of OpSens for total consideration of approximately $254.5 million, or $243.9 million, net of cash acquired. We financed the acquisition through a combination of cash on hand and borrowings under our senior unsecured revolving credit facility.
Read it in 10-K May 21, 2025 at sec.gov
RemovedMD&A
OpSens offers commercially and clinically validated optical technology for use primarily in interventional cardiology. OpSens’ core products include the SavvyWire®, a sensor-guided 3-in-1 guidewire for TAVR procedures, advancing the workflow of the procedure and enabling potentially shorter hospital stays for patients; and the OptoWire®, a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring Fractional Flow Reserve (“FFR”) and diastolic pressure ratio (“dPR”) to aid clinicians in the diagnosis and treatment of patients with coronary artery disease. OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications. The addition of OpSens expands the Hospital business unit portfolio in the interventional cardiology market and is included in the Hospital reportable segment.
Read it in 10-K May 21, 2025 at sec.gov
RemovedMD&A
During the fourth quarter of fiscal 2025, we incurred $0.6 million of restructuring related costs related to the first action under this initiative, which were approved by our Board of Directors in January 2025. Total cumulative charges under this initiative are $0.6 million as of March 29, 2025.
Read it in 10-K May 21, 2025 at sec.gov
RemovedMD&A
of care around the world. The HAS-100 and HAS-300 are currently commercialized in China, where there has been a significant reduction in government reimbursement for testing and enforcement of strict pricing limitations, both of which constrain the growth potential in the market.
Read it in 10-K May 21, 2025 at sec.gov
RemovedMD&A
Fiscal Year (In thousands) 2025 2024 Reported growth Currency impact Constant currency growth(1) Revenues by business unit(2) Plasma(3) 535,431 569,535 (6.0)% (0.1)% (5.9)% Apheresis 213,134 211,173 0.9% (1.5)% 2.4% Whole Blood 47,990 72,058 (33.4)% (0.1)% (33.3)% Blood Center 261,124 283,231 (7.8)% (1.1)% (6.7)% Interventional Technologies(4) 255,019 174,285 46.3% (0.6)% 46.9% Blood Management Technologies(5) 309,250 282,004 9.7% (0.2)% 9.9% Hospital 564,269 456,289 23.7% (0.3)% 24.0% Total net revenues $ 1,360,824 $ 1,309,055 4.0% (0.3)% 4.3% (1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. See “Management’s Use of Non-GAAP Measures.” (2) Beginning in fiscal 2025, we integrated service revenue within our three business units. Prior periods were conformed to current presentation. (3) Plasma revenue includes CSL U.S. disposables revenue of $12.3 million and $99.8 million in the fourth quarter and full year of fiscal year 2025, respectively, as compared to $36.3 million and $154.53 million in the fourth quarter and full year of fiscal 2024, respectively. (4) Interventional Technologies includes Vascular Closure, Sensor -Guided Technologies and Esophageal Protection product lines of the Hospital business. (5) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.
Read it in 10-K May 21, 2025 at sec.gov
RemovedMD&A
Fiscal Year (In thousands) 2025 2024 % Increase/(Decrease) Research and development $ 62,722 $ 54,435 15.2% % of net revenues 4.6 % 4.2 % Selling, general and administrative $ 436,789 $ 431,780 1.2% % of net revenues 32.1 % 33.0 % Amortization of acquired intangible assets $ 48,261 $ 32,031 50.7% % of net revenues 3.5 % 2.4 % Remeasurement of contingent consideration $ (23,022) $ — n/m % of net revenues (1.7) % — % Gains on divestiture and sale of assets $ — $ (2,000) n/m % of net revenues — % (0.2) % Impairment of intangible assets $ 2,391 $ 10,419 (77.1)% % of net revenues 0.2 % 0.8 % Total operating expenses $ 527,141 $ 526,665 0.1% % of net revenues 38.7 % 40.2 %
Read it in 10-K May 21, 2025 at sec.gov
RewordedMD&A
March 28, 2026 March 29, 2025 (Dollars in thousands) March 29, March 30, 2025 2024 Thousands) Cash and cash equivalents $ 245,440 $ 306,763 Availability under revolving credit facilities(1) $ 178,800 448,697 $ 748,697 Working capital $ 552,280 $ 356,862 $ 468,520 Current ratio 3.0 1.6 2.6 Net debt position(1) position(2) $ (979,140) $ (918,025) $ (628,993) Days sales outstanding ("DSO") 56 55 54 Inventory turnover 1.5 1.4 1.7 (1)Net debt position is the sum of cash and cash equivalents less total debt.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
Our effective reported tax rate for the year ended March 29, 2025 28, 2026 is lower higher than our effective reported tax rate of 22.6% 20.9% for fiscal 2024, 2025, primarily due to the favorable impact of contingent consideration remeasurement and tax benefits attributable to the expiration of the statute of limitations associated with uncertain tax position reserves, positions reserves and contingent consideration benefits recorded in FY25, partially offset by the impact of the jurisdictional mix of earnings.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
Fiscal Year (In thousands) 2025 2024 Reported growth Currency impact Constant currency growth (1) United States $ 1,010,918 $970,007 4.2% —% 4.2% International 349,906 339,048 3.2% (1.5)% 4.7% Net revenues $ 1,360,824 $1,309,055 4.0% (0.3)% 4.3% (1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
Fiscal Year (In thousands) 2025 2024 Reported growth Currency impact Constant currency growth (1) United States $ 1,010,918 $970,007 4.2% —% 4.2% International 349,906 339,048 3.2% (1.5)% 4.7% Net revenues $ 1,360,824 $1,309,055 4.0% (0.3)% 4.3% (1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
Fiscal Year (In thousands) 2025 2024 Reported growth Currency impact Constant currency growth (1) United States $ 1,010,918 $970,007 4.2% —% 4.2% International 349,906 339,048 3.2% (1.5)% 4.7% Net revenues $ 1,360,824 $1,309,055 4.0% (0.3)% 4.3% (1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
Fiscal Year (In thousands) 2025 2024 Reported growth Currency impact Constant currency growth (1) United States $ 1,010,918 $970,007 4.2% —% 4.2% International 349,906 339,048 3.2% (1.5)% 4.7% Net revenues $ 1,360,824 $1,309,055 4.0% (0.3)% 4.3% (1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
Operating activities $ 293,221 $ 181,725 $ 181,751 Investing activities (179,547) (161,895) (322,389) Financing activities (178,460) 108,818 38,157 Effect of exchange rate changes on cash and cash equivalents(1) 3,463 (685) (3,185) Net change in cash and cash equivalents $ (61,323) $ 127,963 $ (105,666) (1) The balance sheet is affected by spot exchange rates used to translate local currency amounts into U.S. dollars.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
The decrease in Blood Center’s reported revenue was primarily driven by declines in the divestiture of our Whole Blood business, which was divested product line in the fourth quarter of fiscal 2025. January 2025, partially offset by favorable product mix and higher volume.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
Without Plasma revenue decreased by 2.0% on an as reported basis and decreased by 2.7% without the effect of foreign exchange, Plasma revenue decreased 5.9% exchange during fiscal 2025 2026 as compared with fiscal 2024. 2025.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
GAAP”), In addition to financial measures in accordance with accounting principles generally accepted in the United States of America (“GAAP”), management uses non-GAAP financial measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
In the fourth quarter of fiscal 2025, we We recognized a benefit of $20.3 $1.9 million and $23.0 million during fiscal 2026 and fiscal 2025, respectively, related to the remeasurement of acquisition related acquisition-related contingent consideration.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
During fiscal 2025, Dollar, 26.4% and 25.7% of our sales in fiscal 2026 and fiscal 2025, respectively, were generated outside the U.S., generally in foreign currencies, yet our reporting currency is the U.S. currencies.
Read it in 10-K May 20, 2026 at sec.gov
Quiet changesMD&A
As a result, there are relatively few customers for our Plasma products, especially in the U.S. where approximately over two-thirds of the world’s source plasma is collected and only a few customers provide the majority of our Plasma revenue.
Read it in 10-K May 20, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HAE/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.